PRNewsWire
01 Jul 2026, 01:07 UTC · 11w ago
Verdict
Headline leans bearish. We score ADMA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
ADMA Biologics is accused of using channel stuffing and undisclosed related party transactions to artificially inflate revenue and growth figures.
So whatAllegations of accounting fraud and revenue manipulation strike at the core of a company's financial integrity and usually lead to significant valuation resets.
More negative than 99% of claims this week
A securities fraud class action lawsuit has been filed against ADMA Biologics for materially false and misleading statements between August 2024 and March 2026.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 91% of claims this week
A Culper Research report alleged that ADMA's reported 2025 growth of 20% was actually -3% in real terms.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities fraud class action lawsuit following allegations of channel stuffing and undisclosed related party transactions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
+5.6%
Price is moving against the score
$8.84 vs $8.37 close before publication (Jun 30) · not market-adjusted
ADMA chart →
